CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding CNS Pharmaceuticals, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 12 | 11 | −1 |
| Shares | 145.6K | 280.4K | +134.8K (+92.6%) |
| Value | $348.7K | $1.34M | +$991.8K (+284.4%) |
New holders (4)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| ADAR1 Capital Management, LLC | 70,000 | $334.6K | 0.02% |
| Vanguard Fiduciary Trust Co | 10,226 | $48.9K | 0.00% |
| Vanguard Capital Management LLC | 6,993 | $33.4K | 0.00% |
| Barclays PLC | 19 | $91 | 0.00% |
Sold out (5)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Geode Capital Management, LLC | 23,189 | $55.7K |
| Sound Income Strategies, LLC | 16 | $36 |
| MAI Capital Management | 3 | $8 |
| Citigroup Inc | 1 | $2 |
| Caitong International Asset Management Co., Ltd | 1 | $2 |